Finance
Results: 34057-34068 of 37128

INEOS QUATTRO FINANCE 2 PLC ANNOUNCES RESULTS OF CASH TENDER OFFER FOR ANY AND ALL OF ITS 3 3/8% SENIOR SECURED NOTES DUE 2026

Issuer Direct Reports Third Quarter 2023 Results - Quarterly Revenue of $7.6 Million, an Increase of 43% from Q3 2022

Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)







